[Federal Register Volume 78, Number 114 (Thursday, June 13, 2013)]
[Notices]
[Page 35637]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-14036]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Prospective Grant of Exclusive License: Modulation of Poliovirus
Replicative Fitness by Deoptimization of Synonymous Codons
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is a notice in accordance with 35 U.S.C. 209(e) and 37
CFR 404.7(a)(1)(i) that the Technology Transfer Office, Centers for
Disease Control and Prevention (CDC), Department of Health and Human
Services (HHS), is considering granting an exclusive license, in the
field of use of vaccine targets for treatment or prevention of diseases
in human health and in animal health, to practice the inventions listed
in the patent applications referred to below to Codagenix Inc., having
a place of business in Stony Brook, New York. The patent rights in
these inventions have been assigned to the government of the United
States of America. The patent applications(s) to be licensed are:
US Provisional Application 60/617,545, filed 10/8/2004, entitled
``Modulation of Poliovirus Replicative Fitness by Deoptimization of
Synonymous Codons''; PCT Application PCT/US05/036241, filed 10/7/
2005, entitled ``Modulation of Poliovirus Replicative Fitness by
Deoptimization of Synonymous Codons''; US National Stage Application
11/576,941, filed 11/19/2007, entitled ``Modulation of Poliovirus
Replicative Fitness by Deoptimization of Synonymous Codons''; and
all related continuing and foreign patents/patent applications for
the technology family. CDC Technology ID No. I-025-04.
Status: Pending.
Priority Date(s): 10/8/2004.
If granted, the licensee will pay CDC royalties in accordance with
the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
Technology
Infections by intracellular pathogens such as viruses, bacteria and
parasites, are cleared in most cases after activation of specific T
cellular immune responses that recognize foreign antigens and eliminate
infected cells. Vaccines against those infectious organisms have been
traditionally developed by administration of whole live attenuated or
inactivated microorganisms. Although research has been performed using
subunit vaccines, the levels of cellular immunity induced are usually
low and not capable of eliciting complete protection against diseases
caused by intracellular microbes. However, CDC inventors discovered
that replacement of one or more natural (or native) codons in a
pathogen with synonymous non-preferred codons can decrease the
replicative fitness of the pathogen, thereby attenuating the pathogen.
The non-preferred synonymous codon(s) encode the same amino acid as the
native codon(s), but have nonetheless been found to reduce a pathogen's
replicative fitness. This invention teaches compositions and methods
that can be used to develop attenuated vaccines having well-defined
levels of replicative fitness and enhanced genetic stabilities.
DATES: Only written comments and/or applications for a license which
are received by CDC on or before July 15, 2013 will be considered.
ADDRESSES: Requests for a copy of these patent applications, inquiries,
comments, and other materials relating to the planned license should be
directed to Donald Prather, J.D., Ph.D., Technology Licensing and
Marketing Specialist, Technology Transfer Office, Centers for Disease
Control and Prevention (CDC), 4770 Buford Highway, Mailstop K-79,
Atlanta, GA 30341, Telephone: (770) 488-8612; Facsimile: (770) 488-
8615; Email: [email protected].
SUPPLEMENTARY INFORMATION: Applications for a license filed in response
to this notice will be treated as objections to the giving of the
planned license. Comments and objections submitted in response to this
notice will not be made available for public inspection, and, to the
extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: June 7, 2013.
J. Ronald Campbell,
Director, Division of Executive Secretariat, Centers for Disease
Control and Prevention.
[FR Doc. 2013-14036 Filed 6-12-13; 8:45 am]
BILLING CODE 4163-18-P